Is there still room for cancer vaccines at the era of checkpoint inhibitors

Vaccines

Volumn 4, Issue 4, 2016, Pages

  Karaki, Soumaya ^a   Anson, Marie ^a   Tran, Thi ^a   Giusti, Delphine ^b   Blanc, Charlotte ^a   Oudard, Stephane ^a,b   Tartour, Eric ^a,b,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Ligue Nationale Contre le Cancer LNCC Equipe Labellisée   (France)

Author keywords

Cancer vaccine; CD40; Checkpoint inhibitors; Combination therapy; CTLA 4; Immunotherapy; OX40; PD 1; PD L1

Indexed keywords

CANCER VACCINE; DNA VACCINE; DOPACHROME TAUTOMERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MONTANIDE ISA 51; NIVOLUMAB; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; TICILIMUMAB;

ANTINEOPLASTIC ACTIVITY; CELL INFILTRATION; FVAX GENE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; LUNG ADENOCARCINOMA; PANCREAS CANCER; REVIEW; TUMOR GROWTH; UPREGULATION;

EID: 85016842928     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines4040037     Document Type: Review

References (147)

1. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372, 320-330. [CrossRef] [PubMed]
2. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443-2454. [CrossRef] [PubMed]
3. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411-422. [CrossRef] [PubMed]
4. Van Poelgeest, M.I., Welters, M.J., Vermeij, R., Stynenbosch, L.F., Loof, N.M., Berends-vanderMeer, D.M., Lowik, M.J., Hamming, I.L., van Esch, E.M., Hellebrekers, B.W., et al. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clin. Cancer Res. 2016, 22, 2342-2350. [CrossRef] [PubMed]
5. Karaki, S., Pere, H., Badoual, C., Tartour, E. Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine. Clin. Cancer Res. 2016, 22, 2317-2319. [CrossRef] [PubMed]
6. Skeate, J.G., Woodham, A.W., Einstein, M.H., Da Silva, D.M., Kast, W.M. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum. Vaccin. Immunother. 2016. [CrossRef] [PubMed]
7. Kim, T.J., Jin, H.T., Hur, S.Y., Yang, H.G., Seo, Y.B., Hong, S.R., Lee, C.W., Kim, S., Woo, J.W., Park, K.S., et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nature Commun. 2014. [CrossRef] [PubMed]
8. Trimble, C.L. HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment. Cancer Immunol. Res. 2014, 2, 937-942. [CrossRef] [PubMed]
9. Sandoval, F., Terme, M., Nizard, M., Badoual, C., Bureau, M.F., Freyburger, L., Clement, O., Marcheteau, E., Gey, A., Fraisse, G., et al. Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Sci. Transl. Med. 2013. [CrossRef] [PubMed]
10. Sun, Y.Y., Peng, S., Han, L., Qiu, J., Song, L., Tsai, Y., Yang, B., Roden, R.B., Trimble, C.L., Hung, C.F., et al. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin. Cancer Res. 2016, 22, 657-669. [CrossRef] [PubMed]
11. Nizard, M., Roussel, H., Tartour, E. Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines. Clin. Cancer Res. 2016, 22, 530-532. [CrossRef] [PubMed]
12. Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348, 803-808. [CrossRef] [PubMed]
13. Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016, 534, 396-401. [CrossRef] [PubMed]
14. Melief, C.J., van der Burg, S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nature Rev. Cancer 2008, 8, 351-360. [CrossRef] [PubMed]
15. Stanton, S.E., Disis, M.L. Designing vaccines to prevent breast cancer recurrence or invasive disease. Immunotherapy 2015, 7, 69-72. [CrossRef] [PubMed]
16. Tran, T., Diniz, M.O., Dransart, E., Gey, A., Merillon, N., Lone, Y.C., Godefroy, S., Sibley, C., Ferreira, L.C., Medioni, J., et al. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. Clin. Cancer Res. 2016, 22, 4133-4144. [CrossRef] [PubMed]
17. Melief, C.J., van Hall, T., Arens, R., Ossendorp, F., van der Burg, S.H. Therapeutic cancer vaccines. J. Clin. Investig. 2015, 125, 3401-3412. [CrossRef] [PubMed]
18. Butterfield, L.H. Cancer vaccines. Br. Med. J. 2015. [CrossRef] [PubMed]
19. Combe, P., de Guillebon, E., Thibault, C., Granier, C., Tartour, E., Oudard, S. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology 2015. [CrossRef] [PubMed]
20. Van der Sluis, T.C., van Duikeren, S., Huppelschoten, S., Jordanova, E.S., Beyranvand Nejad, E., Sloots, A., Boon, L., Smit, V.T., Welters, M.J., Ossendorp, F., et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin. Cancer Res. 2015, 21, 781-794. [CrossRef] [PubMed]
21. Quoix, E., Lena, H., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., Gervais, R., Ottensmeier, C., Szczesna, A., Kazarnowicz, A., et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016, 17, 212-223. [CrossRef]
22. Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clemenson, C., Dugue, D., Maroun, P., Louvet, E., Adam, J., et al. Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Mol. Cancer Ther. 2015, 14, 1336-1345. [CrossRef] [PubMed]
23. Oudard, S., Rixe, O., Beuselinck, B., Linassier, C., Banu, E., Machiels, J.P., Baudard, M., Ringeisen, F., Velu, T., Lefrere-Belda, M.A., et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol. Immunother. 2011, 60, 261-271. [CrossRef] [PubMed]
24. Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011, 30, 83-95. [CrossRef] [PubMed]
25. Ramlau, R., Quoix, E., Rolski, J., Pless, M., Lena, H., Levy, E., Krzakowski, M., Hess, D., Tartour, E., Chenard, M.P., et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J. Thorac. Oncol. 2008, 3, 735-744. [CrossRef] [PubMed]
26. Morse, M.A., Lyerly, H.K. Checkpoint blockade in combination with cancer vaccines. Vaccine 2015, 33, 7377-7385. [CrossRef] [PubMed]
27. Gibney, G., Hamid, O., Lutzky, J., Olszanski, A., Gangadhar, T.C., Gajewski, T.F., Chmielewski, B., Hanks, B., Boasberg, P., Zhao, Y., et al. Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. Eur. J. Cancer 2015, 51, S106-S107. [CrossRef]
28. Gangadhar, T., Hamid, O., Smith, D., Bauer, T., Wasser, J., Luke, J., Balmanoukian, A., Kaufman, D.R., Zhao, Y., Maleski, J., et al. Preliminary results from a phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J. Immunother. Cancer 2015. [CrossRef]
29. Vilgelm, A.E., Johnson, D.B., Richmond, A. Combinatorial approach to cancer immunotherapy: Strength in numbers. J. Leukoc. Biol. 2016, 100, 275-290. [CrossRef] [PubMed]
30. Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.M., Sander, C., Janjic, B., Tarhini, A.A., Tawbi, H.A., Kirkwood, J.M., Moschos, S., et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 2014, 74, 1045-1055. [CrossRef] [PubMed]
31. Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013, 73, 128-138. [CrossRef] [PubMed]
32. Sultan, H., Fesenkova, V.I., Addis, D., Fan, A.E., Kumai, T., Wu, J., Salazar, A.M., Celis, E. Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol. Immunother. 2016. [CrossRef] [PubMed]
33. Badoual, C., Pere, H., Roussel, H., Si Mohamed, A., Tartour, E. Cancers of the upper aerodigestive tract associated with human papillomavirus. Med. Sci. 2013, 29, 83-88.
34. Lyford-Pike, S., Peng, S., Young, G.D., Taube, J.M., Westra, W.H., Akpeng, B., Bruno, T.C., Richmon, J.D., Wang, H., Bishop, J.A., et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013, 73, 1733-1741. [CrossRef] [PubMed]
35. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., et al. Colocalization of inflammatory response with b7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012. [CrossRef] [PubMed]
36. Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., Tartour, E. Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance. Cancer Microenviron. 2012. [CrossRef] [PubMed]
37. Pere, H., Montier, Y., Bayry, J., Quintin-Colonna, F., Merillon, N., Dransart, E., Badoual, C., Gey, A., Ravel, P., Marcheteau, E., et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self-antigens. Blood 2011, 118, 4853-4862. [CrossRef] [PubMed]
38. Butt, A.Q., Mills, K.H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014, 33, 4623-4631. [CrossRef] [PubMed]
39. Pere, H., Tanchot, C., Bayry, J., Terme, M., Taieb, J., Badoual, C., Adotevi, O., Merillon, N., Marcheteau, E., Quillien, V.R., et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012, 1, 326-333. [CrossRef] [PubMed]
40. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210, 1695-1710. [CrossRef] [PubMed]
41. Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S.M., Ettenberg, S., Knee, D.A., Wilson, N.S., Dranoff, G., Brogdon, J.L. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 2013, 210, 1685-1693. [CrossRef] [PubMed]
42. Hirschhorn-Cymerman, D., Rizzuto, G.A., Merghoub, T., Cohen, A.D., Avogadri, F., Lesokhin, A.M., Weinberg, A.D., Wolchok, J.D., Houghton, A.N. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 2009, 206, 1103-1116. [CrossRef] [PubMed]
43. Voo, K.S., Bover, L., Harline, M.L., Vien, L.T., Facchinetti, V., Arima, K., Kwak, L.W., Liu, Y.J. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J. Immunol. 2013, 191, 3641-3650. [CrossRef] [PubMed]
44. Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J.P., Sakaguchi, S., Old, L.J., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 2010, 16, 2781-2791. [CrossRef] [PubMed]
45. Ock, C.Y., Keam, B., Kim, S., Lee, J.S., Kim, M., Kim, T.M., Jeon, Y.K., Kim, D.W., Chung, D.H., Heo, D.S. Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clin. Cancer Res. 2016, 22, 2261-2270. [CrossRef] [PubMed]
46. Teng, M.W., Ngiow, S.F., Ribas, A., Smyth, M.J. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015, 75, 2139-2145. [CrossRef] [PubMed]
47. Gajewski, T.F. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin. Oncol. 2015, 42, 663-671. [CrossRef] [PubMed]
48. Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.Y., Mendrzyk, R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18, 1254-1261. [CrossRef] [PubMed]
49. Fong, L., Carroll, P., Weinberg, V., Chan, S., Lewis, J., Corman, J., Amling, C.L., Stephenson, R.A., Simko, J., Sheikh, N.A., et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst. 2014. [CrossRef] [PubMed]
50. Duraiswamy, J., Kaluza, K.M., Freeman, G.J., Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73, 3591-3603. [CrossRef] [PubMed]
51. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 2012, 12, 252-264. [CrossRef] [PubMed]
52. Hurwitz, A.A., Yu, T.F., Leach, D.R., Allison, J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95, 10067-10071. [CrossRef] [PubMed]
53. van Elsas, A., Hurwitz, A.A., Allison, J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999, 190, 355-366. [PubMed]
54. Hurwitz, A.A., Foster, B.A., Kwon, E.D., Truong, T., Choi, E.M., Greenberg, N.M., Burg, M.B., Allison, J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000, 60, 2444-2448. [PubMed]
55. Wada, S., Jackson, C.M., Yoshimura, K., Yen, H.R., Getnet, D., Harris, T.J., Goldberg, M.V., Bruno, T.C., Grosso, J.F., Durham, N., et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J. Transl. Med. 2013. [CrossRef] [PubMed]
56. Curran, M.A., Allison, J.P. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009, 69, 7747-7755. [CrossRef] [PubMed]
57. Davila, E., Kennedy, R., Celis, E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003, 63, 3281-3288. [PubMed]
58. Daftarian, P., Song, G.Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D.J., Ellenhorn, J.D. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res. 2004, 64, 5407-5414. [CrossRef] [PubMed]
59. Met, O., Wang, M., Pedersen, A.E., Nissen, M.H., Buus, S., Claesson, M.H. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 2006, 231, 247-256. [CrossRef] [PubMed]
60. Pedersen, A.E., Buus, S., Claesson, M.H. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett. 2006, 235, 229-238. [CrossRef] [PubMed]
61. Cho, H.I., Jung, S.H., Sohn, H.J., Celis, E., Kim, T.G. An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects. Oncoimmunology 2015. [CrossRef] [PubMed]
62. Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D.J., Ellenhorn, J.D. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J. Immunol. 2003, 170, 3401-3407. [CrossRef] [PubMed]
63. Chakraborty, M., Schlom, J., Hodge, J.W. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol. Immunother. 2007, 56, 1471-1484. [CrossRef] [PubMed]
64. Curran, M.A., Montalvo, W., Yagita, H., Allison, J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 2010, 107, 4275-4280. [CrossRef] [PubMed]
65. Duraiswamy, J., Freeman, G.J., Coukos, G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013, 73, 6900-6912. [CrossRef] [PubMed]
66. Binder, D.C., Engels, B., Arina, A., Yu, P., Slauch, J.M., Fu, Y.X., Karrison, T., Burnette, B., Idel, C., Zhao, M., et al. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol. Res. 2013, 1, 123-133. [CrossRef] [PubMed]
67. Linch, S.N., Kasiewicz, M.J., McNamara, M.J., Hilgart-Martiszus, I.F., Farhad, M., Redmond, W.L. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc. Natl. Acad. Sci. USA 2016, 113, E319-E327. [CrossRef] [PubMed]
68. Ge, Y., Xi, H., Ju, S., Zhang, X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 2013, 336, 253-259. [CrossRef] [PubMed]
69. Fu, J., Malm, I.J., Kadayakkara, D.K., Levitsky, H., Pardoll, D., Kim, Y.J. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res. 2014, 74, 4042-4052. [CrossRef] [PubMed]
70. Mkrtichyan, M., Najjar, Y.G., Raulfs, E.C., Abdalla, M.Y., Samara, R., Rotem-Yehudar, R., Cook, L., Khleif, S.N. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur. J. Immunol. 2011, 41, 2977-2986. [CrossRef] [PubMed]
71. Ahrends, T., Babala, N., Xiao, Y., Yagita, H., van Eenennaam, H., Borst, J. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016, 76, 2921-2931. [CrossRef] [PubMed]
72. Lasaro, M.O., Sazanovich, M., Giles-Davis, W., Mrass, P., Bunte, R.M., Sewell, D.A., Hussain, S.F., Fu, Y.X., Weninger, W., Paterson, Y., et al. Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol. Ther. 2011, 19, 1727-1736. [CrossRef] [PubMed]
73. Le Mercier, I., Chen, W., Lines, J.L., Day, M., Li, J., Sergent, P., Noelle, R.J., Wang, L. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 2014, 74, 1933-1944. [CrossRef] [PubMed]
74. Sawada, Y., Yoshikawa, T., Shimomura, M., Iwama, T., Endo, I., Nakatsura, T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 2015, 46, 28-36. [CrossRef] [PubMed]
75. Williams, E.L., Dunn, S.N., James, S., Johnson, P.W., Cragg, M.S., Glennie, M.J., Gray, J.C. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin. Cancer Res. 2013, 19, 3545-3555. [CrossRef] [PubMed]
76. Dos Santos, L.I., Galvao-Filho, B., de Faria, P.C., Junqueira, C., Dutra, M.S., Teixeira, S.M., Rodrigues, M.M., Ritter, G., Bannard, O., Fearon, D.T., et al. Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. Cancer Immunol. Immunother. 2015, 64, 311-323. [CrossRef] [PubMed]
77. Sierro, S.R., Donda, A., Perret, R., Guillaume, P., Yagita, H., Levy, F., Romero, P. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur. J. Immunol. 2011, 41, 2217-2228. [CrossRef] [PubMed]
78. Soares, K.C., Rucki, A.A., Wu, A.A., Olino, K., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E., Lutz, E., Liu, L., et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother. 2015. [CrossRef] [PubMed]
79. Son, C.H., Bae, J.H., Shin, D.Y., Lee, H.R., Choi, Y.J., Jo, W.S., Ho Jung, M., Kang, C.D., Yang, K., Park, Y.S. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. J. Immunother. 2014, 37, 1-7. [CrossRef] [PubMed]
80. Macri, C., Dumont, C., Johnston, A.P., Mintern, J.D. Targeting dendritic cells: A promising strategy to improve vaccine effectiveness. Clin. Transl. Immunol. 2016. [CrossRef] [PubMed]
81. Lehmann, C.H., Heger, L., Heidkamp, G.F., Baranska, A., Luhr, J.J., Hoffmann, A., Dudziak, D. Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines 2016. [CrossRef] [PubMed]
82. Haicheur, N., Bismuth, E., Bosset, S., Adotevi, O., Warnier, G., Lacabanne, V., Regnault, A., Desaymard, C., Amigorena, S., Ricciardi-Castagnoli, P., et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 2000, 165, 3301-3308. [CrossRef] [PubMed]
83. Lee, R.S., Tartour, E., van der Bruggen, P., Vantomme, V., Joyeux, I., Goud, B., Fridman, W.H., Johannes, L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 1998, 28, 2726-2737. [CrossRef]
84. Adotevi, O., Vingert, B., Freyburger, L., Shrikant, P., Lone, Y.C., Quintin-Colonna, F., Haicheur, N., Amessou, M., Herbelin, A., Langlade-Demoyen, P., et al. B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity. J. Immunol. 2007, 179, 3371-3379. [CrossRef] [PubMed]
85. Rekoske, B.T., Smith, H.A., Olson, B.M., Maricque, B.B., McNeel, D.G. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol. Res. 2015, 3, 946-955. [CrossRef] [PubMed]
86. Xue, W., Metheringham, R.L., Brentville, V.A., Gunn, B., Symonds, P., Yagita, H., Ramage, J.M., Durrant, L.G. SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology 2016. [CrossRef] [PubMed]
87. Grosso, J.F., Kelleher, C.C., Harris, T.J., Maris, C.H., Hipkiss, E.L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T.C., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine selfand tumor-tolerance systems. J. Clin. Invest. 2007, 117, 3383-3392. [CrossRef] [PubMed]
88. Baghdadi, M., Nagao, H., Yoshiyama, H., Akiba, H., Yagita, H., Dosaka-Akita, H., Jinushi, M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol. Immunother. 2013, 62, 629-637. [CrossRef] [PubMed]
89. Wang, L., Rubinstein, R., Lines, J.L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.F., Gondek, D., Wang, Y., Fava, R.A., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011, 208, 577-592. [CrossRef] [PubMed]
90. Lines, J.L., Sempere, L.F., Broughton, T., Wang, L., Noelle, R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol. Res. 2014, 2, 510-517. [CrossRef] [PubMed]
91. Song, M.Y., Park, S.H., Nam, H.J., Choi, D.H., Sung, Y.C. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J. Immunother. 2011, 34, 297-306. [CrossRef] [PubMed]
92. Zhang, Y., Ertl, H.C. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. J. Immunol. 2014, 193, 1836-1846. [CrossRef] [PubMed]
93. Han, L., Wang, W., Lu, J., Kong, F., Ma, G., Zhu, Y., Zhao, D., Zhu, J., Shuai, W., Zhou, Q., et al. AAV-sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo. Cancer Lett. 2014, 354, 398-406. [CrossRef] [PubMed]
94. Han, L., Wang, W., Fang, Y., Feng, Z., Liao, S., Li, W., Li, Y., Li, C., Maitituoheti, M., Dong, H., et al. Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo. J. Immunol. 2009, 183, 7842-7850. [CrossRef] [PubMed]
95. Cohen, A.D., Diab, A., Perales, M.A., Wolchok, J.D., Rizzuto, G., Merghoub, T., Huggins, D., Liu, C., Turk, M.J., Restifo, N.P., et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006, 66, 4904-4912. [CrossRef] [PubMed]
96. Avogadri, F., Merghoub, T., Maughan, M.F., Hirschhorn-Cymerman, D., Morris, J., Ritter, E., Olmsted, R., Houghton, A.N., Wolchok, J.D. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS ONE 2010. [CrossRef] [PubMed]
97. Bartkowiak, T., Singh, S., Yang, G., Galvan, G., Haria, D., Ai, M., Allison, J.P., Sastry, K.J., Curran, M.A. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc. Natl. Acad. Sci. USA 2015, 112, E5290-E5299. [CrossRef] [PubMed]
98. Lathrop, S.K., Huddleston, C.A., Dullforce, P.A., Montfort, M.J., Weinberg, A.D., Parker, D.C. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J. Immunol. 2004, 172, 6735-6743. [CrossRef] [PubMed]
99. Chen, A.I., McAdam, A.J., Buhlmann, J.E., Scott, S., Lupher, M.L., Jr., Greenfield, E.A., Baum, P.R., Fanslow, W.C., Calderhead, D.M., Freeman, G.J., et al. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999, 11, 689-698. [CrossRef]
100. Murata, K., Ishii, N., Takano, H., Miura, S., Ndhlovu, L.C., Nose, M., Noda, T., Sugamura, K. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 2000, 19, 365-374. [CrossRef]
101. den Boer, A.T., Diehl, L., van Mierlo, G.J., van der Voort, E.I., Fransen, M.F., Krimpenfort, P., Melief, C.J., Offringa, R., Toes, R.E. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 2001, 167, 2522-2528. [CrossRef] [PubMed]
102. Carlring, J., Szabo, M.J., Dickinson, R., De Leenheer, E., Heath, A.W. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. Blood 2012, 119, 2056-2065. [CrossRef] [PubMed]
103. Cho, H.I., Celis, E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009, 69, 9012-9019. [CrossRef] [PubMed]
104. Hassan, H.A., Smyth, L., Wang, J.T., Costa, P.M., Ratnasothy, K., Diebold, S.S., Lombardi, G., Al-Jamal, K.T. Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. Biomaterials 2016, 104, 310-322. [CrossRef] [PubMed]
105. Murata, S., Ladle, B.H., Kim, P.S., Lutz, E.R., Wolpoe, M.E., Ivie, S.E., Smith, H.M., Armstrong, T.D., Emens, L.A., Jaffee, E.M., et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol. 2006, 176, 974-983. [CrossRef] [PubMed]
106. De Smedt, T., Smith, J., Baum, P., Fanslow, W., Butz, E., Maliszewski, C. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 2002, 168, 661-670. [CrossRef] [PubMed]
107. Das, R., Verma, R., Sznol, M., Boddupalli, C.S., Gettinger, S.N., Kluger, H., Callahan, M., Wolchok, J.D., Halaban, R., Dhodapkar, M.V., et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 2015, 194, 950-959. [CrossRef] [PubMed]
108. Sorensen, M.R., Holst, P.J., Steffensen, M.A., Christensen, J.P., Thomsen, A.R. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010, 28, 6757-6764. [CrossRef] [PubMed]
109. Ito, D., Ogasawara, K., Matsushita, K., Morohashi, T., Namba, K., Matsuki, N., Kitaichi, N., Inuyama, Y., Hosokawa, M., Nakayama, E., et al. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies. Immunobiology 2000, 201, 527-540. [CrossRef]
110. McGray, A.J., Bernard, D., Hallett, R., Kelly, R., Jha, M., Gregory, C., Bassett, J.D., Hassell, J.A., Pare, G., Wan, Y., et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 2012, 1, 419-431. [CrossRef] [PubMed]
111. Saha, A., Chatterjee, S.K. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand. J. Immunol. 2010, 71, 70-82. [CrossRef] [PubMed]
112. Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N., Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R., Melief, C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001, 194, 823-832. [CrossRef] [PubMed]
113. Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., Sharma, P. CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. USA 2008, 105, 14987-14992. [CrossRef] [PubMed]
114. Sarnaik, A.A., Yu, B., Yu, D., Morelli, D., Hall, M., Bogle, D., Yan, L., Targan, S., Solomon, J., Nichol, G., et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 2011, 17, 896-906. [CrossRef] [PubMed]
115. Mahony, D., Morris, J.C., Quinn, C., Gao, W., Wilson, W.H., Gause, B., Pittaluga, S., Neelapu, S., Brown, M., Fleisher, T.A., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 2007, 13, 958-964. [CrossRef] [PubMed]
116. Kavanagh, B., O’Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J.P., Small, E.J., Fong, L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008, 112, 1175-1183. [CrossRef] [PubMed]
117. Aida, K., Miyakawa, R., Suzuki, K., Narumi, K., Udagawa, T., Yamamoto, Y., Chikaraishi, T., Yoshida, T., Aoki, K. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-alpha gene therapy for pancreatic cancer. Cancer Sci. 2014, 105, 159-167. [CrossRef] [PubMed]
118. Menard, C., Ghiringhelli, F., Roux, S., Chaput, N., Mateus, C., Grohmann, U., Caillat-Zucman, S., Zitvogel, L., Robert, C. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin. Cancer Res. 2008, 14, 5242-5249. [CrossRef] [PubMed]
119. Weber, J.S., Kudchadkar, R.R., Yu, B., Gallenstein, D., Horak, C.E., Inzunza, H.D., Zhao, X., Martinez, A.J., Wang, W., Gibney, G., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J. Clin. Oncol. 2013, 31, 4311-4318. [CrossRef] [PubMed]
120. Avogadri, F., Zappasodi, R., Yang, A., Budhu, S., Malandro, N., Hirschhorn-Cymerman, D., Tiwari, S., Maughan, M.F., Olmsted, R., Wolchok, J.D., et al. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol. Res. 2014, 2, 448-458. [CrossRef] [PubMed]
121. Vu, M.D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., Killeen, N., Ishii, N., Li, X.C. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007, 110, 2501-2510. [CrossRef] [PubMed]
122. Pico de Coana, Y., Poschke, I., Gentilcore, G., Mao, Y., Nystrom, M., Hansson, J., Masucci, G.V., Kiessling, R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol. Res. 2013, 1, 158-162. [CrossRef] [PubMed]
123. Feder-Mengus, C., Schultz-Thater, E., Oertli, D., Marti, W.R., Heberer, M., Spagnoli, G.C., Zajac, P. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum. Gene Ther. 2005, 16, 348-360. [CrossRef] [PubMed]
124. Pruitt, S.K., Boczkowski, D., de Rosa, N., Haley, N.R., Morse, M.A., Tyler, D.S., Dannull, J., Nair, S. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur. J. Immunol. 2011, 41, 3553-3563. [CrossRef] [PubMed]
125. Bonehill, A., Tuyaerts, S., Van Nuffel, A.M., Heirman, C., Bos, T.J., Fostier, K., Neyns, B., Thielemans, K. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther. 2008, 16, 1170-1180. [CrossRef] [PubMed]
126. Wilgenhof, S., Van Nuffel, A.M., Benteyn, D., Corthals, J., Aerts, C., Heirman, C., Van Riet, I., Bonehill, A., Thielemans, K., Neyns, B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann. Oncol. 2013, 24, 2686-2693. [CrossRef] [PubMed]
127. Van den Eertwegh, A.J., Versluis, J., van den Berg, H.P., Santegoets, S.J., van Moorselaar, R.J., van der Sluis, T.M., Gall, H.E., Harding, T.C., Jooss, K., Lowy, I., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13, 509-517. [CrossRef]
128. Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723. [CrossRef] [PubMed]
129. Bjoern, J., Iversen, T.Z., Nitschke, N.J., Andersen, M.H., Svane, I.M. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy 2016, 18, 1043-1055. [CrossRef] [PubMed]
130. Attia, P., Phan, G.Q., Maker, A.V., Robinson, M.R., Quezado, M.M., Yang, J.C., Sherry, R.M., Topalian, S.L., Kammula, U.S., Royal, R.E., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23, 6043-6053. [CrossRef] [PubMed]
131. Rosenberg, S.A., Yang, J.C., Restifo, N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10, 909-915. [CrossRef] [PubMed]
132. Ribas, A., Comin-Anduix, B., Chmielowski, B., Jalil, J., de la Rocha, P., McCannel, T.A., Ochoa, M.T., Seja, E., Villanueva, A., Oseguera, D.K., et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 2009, 15, 6267-6276. [CrossRef] [PubMed]
133. Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., Neyns, B. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. J. Clin. Oncol. 2016, 34, 1330-1338. [CrossRef] [PubMed]
134. Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., Jr., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11, 155-164. [CrossRef]
135. O’Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 2010, 21, 1712-1717. [CrossRef] [PubMed]
136. Madan, R.A., Mohebtash, M., Arlen, P.M., Vergati, M., Rauckhorst, M., Steinberg, S.M., Tsang, K.Y., Poole, D.J., Parnes, H.L., Wright, J.J., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 2012, 13, 501-508. [CrossRef]
137. Jochems, C., Tucker, J.A., Tsang, K.Y., Madan, R.A., Dahut, W.L., Liewehr, D.J., Steinberg, S.M., Gulley, J.L., Schlom, J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol. Immunother. 2014, 63, 407-418. [CrossRef] [PubMed]
138. Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., Glode, L.M., Bilhartz, D.L., Wyand, M., Manson, K., Panicali, D.L., Laus, R., Schlom, J., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28, 1099-1105. [CrossRef] [PubMed]
139. Nesselhut, J., Marx, D., Lange, H., Regalo, G., Cillien, N., Chang, R.Y., Nesselhut, T. Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer. In Proceedings of ASCO Annual Meeting, Chicago, IL, USA, 2-6 June 2016.
140. Gibney, G.T., Kudchadkar, R.R., DeConti, R.C., Thebeau, M.S., Czupryn, M.P., Tetteh, L., Eysmans, C., Richards, A., Schell, M.J., Fisher, K.J., et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin. Cancer Res. 2015, 21, 712-720. [CrossRef] [PubMed]
141. Liu, Z., Zhou, H., Wang, W., Fu, Y.X., Zhu, M. A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. Oncoimmunology 2016. [CrossRef] [PubMed]
142. Chambers, C.A., Kuhns, M.S., Egen, J.G., Allison, J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Ann. Rev. Immunol. 2001, 19, 565-594. [CrossRef] [PubMed]
143. Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A.J., Brown, J.A., Nunes, R., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2001, 2, 261-268. [CrossRef] [PubMed]
144. Brown, J.A., Dorfman, D.M., Ma, F.R., Sullivan, E.L., Munoz, O., Wood, C.R., Greenfield, E.A., Freeman, G.J. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 2003, 170, 1257-1266. [CrossRef] [PubMed]
145. Gregor, P.D., Wolchok, J.D., Ferrone, C.R., Buchinshky, H., Guevara-Patino, J.A., Perales, M.A., Mortazavi, F., Bacich, D., Heston, W., Latouche, J.B., et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self-antigens in animal and cellular model systems. Vaccine 2004, 22, 1700-1708. [CrossRef] [PubMed]
146. Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., Gandhi, L., Redig, A.J., Rodig, S.J., Asahina, H., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Commun. 2016. [CrossRef] [PubMed]
147. Manlove, L.S., Schenkel, J.M., Manlove, K.R., Pauken, K.E., Williams, R.T., Vezys, V., Farrar, M.A. Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J. Immunol. 2016, 196, 4793-4804. [CrossRef] [PubMed]